Patents by Inventor Jeffrey S. SWERS
Jeffrey S. SWERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250320271Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: February 6, 2025Publication date: October 16, 2025Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Patent number: 12421291Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: GrantFiled: September 28, 2022Date of Patent: September 23, 2025Assignee: Arcellx, Inc.Inventors: David M. Hilbert, Jeffrey S. Swers
-
Publication number: 20250154224Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: January 17, 2025Publication date: May 15, 2025Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Publication number: 20250026849Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo.Type: ApplicationFiled: August 26, 2024Publication date: January 23, 2025Inventors: David M. HILBERT, Jeffrey S. SWERS, David William LAFLEUR
-
Publication number: 20240156866Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.Type: ApplicationFiled: June 28, 2023Publication date: May 16, 2024Inventors: David M. HILBERT, Jeffrey S. SWERS, David William LAFLEUR
-
Patent number: 11827716Abstract: Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.Type: GrantFiled: November 14, 2022Date of Patent: November 28, 2023Assignee: ARCELLX, INC.Inventors: David Lafleur, Jeffrey S. Swers, Justin Edwards
-
Patent number: 11730763Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.Type: GrantFiled: November 14, 2018Date of Patent: August 22, 2023Assignee: Arcellx, Inc.Inventors: David M. Hilbert, Jeffrey S. Swers, David William Lafleur
-
Publication number: 20230250185Abstract: Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limitefd to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.Type: ApplicationFiled: November 14, 2022Publication date: August 10, 2023Inventors: David LAFLEUR, Jeffrey S. SWERS, Justin EDWARDS
-
Publication number: 20230125550Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: September 28, 2022Publication date: April 27, 2023Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Patent number: 11464803Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: GrantFiled: September 10, 2021Date of Patent: October 11, 2022Assignee: ARCELLX, INC.Inventors: David M. Hilbert, Jeffrey S. Swers
-
Patent number: 11377482Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: GrantFiled: November 14, 2018Date of Patent: July 5, 2022Assignee: ARCELLX, INC.Inventors: David M. Hilbert, Jeffrey S. Swers
-
Patent number: 11318165Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: GrantFiled: September 10, 2021Date of Patent: May 3, 2022Assignee: ARCELLX, INC.Inventors: David M. Hilbert, Jeffrey S. Swers
-
Publication number: 20220056105Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: November 14, 2018Publication date: February 24, 2022Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Publication number: 20210401891Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: September 10, 2021Publication date: December 30, 2021Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Publication number: 20210403517Abstract: D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.Type: ApplicationFiled: September 10, 2021Publication date: December 30, 2021Inventors: David M. HILBERT, Jeffrey S. SWERS
-
Publication number: 20210023133Abstract: Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo.Type: ApplicationFiled: November 14, 2018Publication date: January 28, 2021Inventors: David M. HILBERT, Jeffrey S. SWERS, David William LAFLEUR